Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Sig... Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. Show more
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0541 | 9.29553264605 | 0.582 | 0.6361 | 0.535 | 377402 | 0.55234325 | CS |
4 | -0.0839 | -11.6527777778 | 0.72 | 0.7456 | 0.535 | 353067 | 0.59079581 | CS |
12 | -0.1289 | -16.8496732026 | 0.765 | 0.96 | 0.535 | 367683 | 0.72824401 | CS |
26 | -0.6839 | -51.8106060606 | 1.32 | 1.51 | 0.535 | 436223 | 0.99901224 | CS |
52 | -1.7039 | -72.8162393162 | 2.34 | 3.405 | 0.535 | 837250 | 1.58754709 | CS |
156 | -107.4539 | -99.4115089277 | 108.09 | 112.87 | 0.535 | 1347084 | 7.00502467 | CS |
260 | -78.5339 | -99.1965390931 | 79.17 | 157.98 | 0.535 | 923978 | 17.77490495 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales